Reddit Posts
$IFUS Trash to Cash story, Cattle feed game changer has hit National Real Journalists TV on RVT-TV
Mentions
There are barely any small cap ETFs worth mentioning as most rely on factor divisions or disproportionate weighting instead of quality filters. AVUV, AVSC, GSC, EBIT, RVT, and XSHQ are the best picks IMO but a few of them charge exorbitant expense ratios. Besides that, the small cap and mid cap spaces are a stock picker's game. You don't want the multitude of debt-ridden, unprofitable companies weighing down on the big winners.
Try GAB , the fund pays 10% annual return. AGNC pays 15% , ET pays 8%, RVT pays 7%
[Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant](https://www.globenewswire.com/news-release/2023/10/23/2764359/34323/en/Roche-Enters-Into-a-Definitive-Agreement-to-Acquire-Telavant-Including-Rights-to-Novel-TL1A-Directed-Antibody-RVT-3101-for-the-Treatment-of-Inflammatory-Bowel-Disease-From-Roivant.html) \- ROIV "Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million" "Telavant was jointly formed by Roivant and Pfizer in 2022 to develop and commercialize RVT-3101 in the US and Japan. Roivant owns 75% of the issued and outstanding shares of common stock and preferred stock of Telavant and Pfizer owns the remaining 25%."
For any biotech bros, Roivant ($ROIV) in focus this morning: * [Roche $8.1B takeout of Telavant](https://www.globenewswire.com/news-release/2023/10/23/2764359/0/en/Roche-Enters-Into-a-Definitive-Agreement-to-Acquire-Telavant-Including-Rights-to-Novel-TL1A-Directed-Antibody-RVT-3101-for-the-Treatment-of-Inflammatory-Bowel-Disease-From-Roivant.html) * Telavant is joint venture Roivant+Pfizer * Irritable Bowel Disease antibody treatment * Roivant hosting a [call about it at 8 AM EST](https://investor.roivant.com/news-events/events)
I recommend you take another look. Not every drug they researched worked out, but the ones that do work are massive successes for them. For example, they formed their Urovant subsidiary to research [Vibegron](https://en.wikipedia.org/wiki/Vibegron#) after Merck lost interest, and after just a few years (because of their successful trials) sold Urovant to Sumitomo pharma as part of a [$3B deal](https://medcitynews.com/2019/09/sumitomo-pays-3b-to-vivek-ramaswamys-roivant-under-new-alliance/) They are also in talks to sell their bowel drug **RVT-3101** to [Roche for $7B](https://www.bloomberg.com/news/articles/2023-07-06/roivant-said-to-attract-interest-for-7-billion-plus-bowel-drug) after it helped 32% of Ulcerative Collitis patients achieve remission in [phase II trials](https://www.statnews.com/2023/01/04/roivant-pfizer-inflammatory-bowel-drug-ulcerative-colitis/). Keep in mind the market cap of the entire ROIV company is $9B, and RVT-3101 is just one of many drugs they're working on. So, while I think his hedge fund connects definitely helped, I'd say the company is much more than the "smoke and mirrors" operation people often describe it as.
Smoke and mirrors with the buyback. Numbers were dull so they had to distract. No better ideas to deploy capital? Seemingly everyone missed it, but ex Palantir SPAC Roivant was the accompanying play from May. RVT-3101 seems to be something special, and Roche is circling with others. Not clear if Foundry helped in finding it. I will hold until the sale announcement, but maybe they just keep it in the end. Another SPAC , CELU, has great shareholder communication. Vivek will be on the big stage next month. Probably playing for the FDA chair, maybe playing for it all. Peter has a candidate in the race. Music to some PLTR ears. I jumped at 19, selling back to the FOMO boys and their lambos. See you before the Titan announcement, hopefully around 12.
OffTopic, bit of a head scratcher. [Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics](https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-acquisition-of-spyre-therapeutics-301858013.html) \- AGLE AGLE is issuing the equivalent ***one billion*** new shares, at 29 cents per share value, in order to but Spyre Theraputics and receive $220 million in cash. The cash is "expected to fund operations into 2026". Existing shareholders of AGLE will own 5,5% of the company, so existing shares are being diluted by about 94.5%. AGLE, which closed yesterday at 12 cents, is up about 390% at the moment at 52 cents, after opening at 90 cents per share. "The company's two parallel lead programs—SPY001 and SPY002—target a4b7 and TL1A, respectively, and build upon the validation of these targets by existing commercial- and clinical-stage antibody therapeutics. Spyre's lead programs are projected to enter clinical studies in 2024, with clinical data for SPY001 expected by YE2024." Roivant [announced positive results this morning on RVT-3101 in a Phase 2b Study](https://www.globenewswire.com/news-release/2023/06/22/2692814/34323/en/Roivant-Reports-Chronic-Period-Data-for-RVT-3101-from-the-TUSCANY-2-Phase-2b-Study-in-Ulcerative-Colitis-Demonstrating-Improved-Efficacy-from-the-Induction-to-Chronic-Period.html), which is "an anti-TL1A antibody". ROIV is up 10% today, ROIVW is up 15%.
[Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis](https://www.globenewswire.com/news-release/2023/06/21/2692527/34323/en/Roivant-to-Host-Investor-Call-at-8-00-AM-ET-on-Thursday-June-22-to-Review-Results-from-the-Chronic-Period-of-TUSCANY-2-a-Large-Global-Phase-2b-Study-of-RVT-3101-Anti-TL1A-Antibody-.html) \- ROIV ROIVW Might be worth keeping an eye on ROIV tomorrow morning. "[The commercial markets for these diseases for advanced therapies](https://www.sec.gov/Archives/edgar/data/1635088/000114036122043937/brhc10044960_ex99-1.htm#:~:text=The%20commercial%20markets%20for%20these%20diseases) is nearly $15 billion per year in the US alone and growing. Available treatments have very low remission rates, and thus there is a large need for an efficacious and safe therapy." Possible that RIOIV could go up or down quite a bit tomorrow, based on the announced results. ROIV was abour $3 last September, closed at $9.53 today.
I'm a bot, *bleep*, *bloop*. Someone has linked to this thread from another place on reddit: - [/r/citadelllc] [$IFUS Trash to Cash story, Cattle feed game changer has hit National Real Journalists TV on RVT-TV](https://www.reddit.com/r/CitadelLLC/comments/133709x/ifus_trash_to_cash_story_cattle_feed_game_changer/) *^(If you follow any of the above links, please respect the rules of reddit and don't vote in the other threads.) ^\([Info](/r/TotesMessenger) ^/ ^[Contact](/message/compose?to=/r/TotesMessenger))*
Currently $ADX $RVT $RMT $RQI $RFI $PDI Getting rid of $PDI soon It might go full on $VT
I'd do an even mix of BST, REMX, HTGC, PDO, SCHD, RVT, JEPI, and PDBC. Average dividend yield of 8+% with decent capital growth, good mix of monthly/quarterly/annual payouts, and most of those should do well in the current economic environment. I'd also reinvest as much of the dividend as possible.
I work doing ultrasound as an RVT. Hospitals are draining. Gotta find yourself an outpatient office. I work now documenting and diagnosing venous issues with legs. Most the doctors I work with were surgeons previously and got burnt out of the hospital system or wanted to slow down so they would have more time with their families. No call, no weekends, no holidays, little more travel than I’d like but not bad. It’s not all roses though, it’s just slightly less crazy. I miss doing other arterial and venous ultrasound, but the job pays the bills and all the coworkers I enjoy.
I use VB(ETF) and RVT(CEF) for small caps whenever I put money there. I prefer blend instead of going value or growth.
Some small cap mutual funds are in my retirement accounts but I also invest in small caps in my taxable account. I found a little winner that I like, RVT. It fits my needs, which is to produce some cash flow (they regularly pay out capital gains and whatever minor dividends are paid) while enjoying the historical returns of small caps. It is a closed end fund, and trades at about a 9% discount to NAV. They have a thirty year track record of beating the Russel 1000 by about ten bps.
Maybe your personality is a better fit for dividend investing and strong value orientation, where you do not need to stress as much about overpaying. There are solid companies that pay strong dividends, where you can sit on the shares and get paid regularly. I’m kind of like this and own MO, SPG, STOR, some index funds to get some growth but they still pay a smaller dividend, RVT (a value small cap manager who pays out gains quarterly), some energy XOM KMI, some high yield bond fund, some preferred, in all the portfolio yields around 4.5%. It used to yield north of 5% when I owned a bunch of BDCs, but I promised myself to sell them after recovering from the pandemic low. With 300K you could make 12-15k pretty conservatively and have a chance at some capital appreciation too.
I’m an RVT. We run bloodwork in clinic every day on machines that sit on a countertop. I’ve seen nothing from Zom that would make me believe a clinic would switch from Abaxis or Idexx machines to theirs.
I am an RVT and I have the same feelings. I had heard about ZOM on here and decided to do a bit of research. Our clinic is small to medium sized (5 small animal doctors) and none of them had ever heard about Truforma. I explained what it was and it didn't really move the needle. We, like most clinics, use IDEXX for our diagnostic machines and I don't think that will change. Truforma is probably going to be too expensive/ too narrow for most small clinics. It might get picked up at larger facilities, specialists, and universities. But I'm not sure it will explode. I bought a small amount and will sell after the hype.
CEF are a fine structure. Love, love, love having cheap leverage to juice returns. Love buying assets at a discount, with the option to sell at a premium if the situation arises. Love managers not having to sell assets if market sentiment changes and people panic sell. Now, pretty much every CEF has capital appreciation as a secondary objective written into their prospectus, but the vast majority utterly fail at this. Returning capital to close discounts and maintaining outsized dividends, most of the time share price sinks over time which does not match my investment needs. Here are ones I own and love. NHS - Nueberger Berman junk bond fund. These guys are badass high yield traders and over the life of the fund have averaged 8.7% returns. Presently paying 8.8%. Share price has declined a bit over time but it’s a sacrifice I’ll make for their expertise. RVT - Royce Value Fund got a big allocation in my portfolio. Royce has beaten the Russell 2000 over 30 years by maybe 30-40bps after fees. That’s damn impressive to beat an index. Small caps are a great asset. Their fees are totally reasonable and they have been around for a long time. Their dividend policy is based on a rolling average of share price, usually between 5-7%. This has allowed them to increase share price over time, albeit with a lot of volatility. Check them out. No leverage. FFC - Flaherty and Crumrine Preferred Income. Except for a case of forced asset selling in the Great Recession, they have not lost asset value. So this fits my wheelhouse. Great managers. Preferred stocks. Some leverage. Had been waiting on an opportunity to buy into this one and got it March 2020. Was watching like a hawk and bought 5000 shares within 2 hours of the bottom. UTF - Cohen and Steers Utility/Infrastructure Fund. Good managers. RQI - Cohen and Steers Quality Realty Income Fund. 4-star Morningstar.
Thinking of selling [this](https://i.imgur.com/RVT6DL0.jpg) sometime tomorrow since it expires and use any profits to purchase shares, dumb move?
I’m an RVT. We run bloodwork in clinic every day, including thyroid levels. ACTH, which is involved in the diagnosis of Cushing’s disease, is one that we send out to a reference lab. It isn’t an emergency condition so a 24 hour turn around time doesn’t matter. It also affects 1-2/1000 dogs so not a big draw to buy a single machine that MAY be effective at a single test, especially considering vets have contracts with reference labs that include leasing of machines to use in-clinic. But what do I know?